DFO
BBIO icon

Duquesne Family Office’s BridgeBio Pharma BBIO Stock Holding History

Duquesne Family Office’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-438,050
Closed -$15.1M – 74
2025
Q1 		$15.1M Buy
+438,050
New +$14.8M 0.49% 41

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Duquesne Family Office's BBIO Position: Q2 2025 in Review

Duquesne Family Office sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 438,050 shares — an estimated $15.1M sold.

Duquesne Family Office first reported a position in BBIO in Q1 2025 and held it in 1 quarter. The position peaked at $15.1M in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

  • Duquesne Family Office reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
  • Duquesne Family Office sold 438,050 BridgeBio Pharma shares in Q2 2025, an estimated $15.1M.
  • Duquesne Family Office first reported a position in BridgeBio Pharma in Q1 2025 and held it in 1 quarter.
  • Duquesne Family Office's BridgeBio Pharma position peaked at $15.1M in Q1 2025.
  • 359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Duquesne Family Office's 13F filing for Q2 2025, filed 15 Aug 2025.